Compare CMTL & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMTL | BDSX |
|---|---|---|
| Founded | 1967 | 2005 |
| Country | United States | United States |
| Employees | 1385 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 162.1M | 122.0M |
| IPO Year | 2024 | 2020 |
| Metric | CMTL | BDSX |
|---|---|---|
| Price | $4.84 | $17.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $6.00 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 224.9K | 145.0K |
| Earning Date | 01-01-0001 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $499,528,000.00 | $88,499,000.00 |
| Revenue This Year | N/A | $23.35 |
| Revenue Next Year | $1.97 | $19.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $1.19 | $0.25 |
| 52 Week High | $6.21 | $20.21 |
| Indicator | CMTL | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 41.58 | 62.15 |
| Support Level | $2.74 | $6.33 |
| Resistance Level | $6.15 | N/A |
| Average True Range (ATR) | 0.36 | 1.86 |
| MACD | -0.06 | 0.08 |
| Stochastic Oscillator | 18.30 | 64.40 |
Comtech Telecommunications Corp is a provider of communications technology and solutions. It operates in two reportable business segments: Satellite and Space Communications and Allerium. The company's Satellite and Space Communications segment, which generates maximum revenue, is organized into four technology areas: satellite modem and amplifier technologies, troposcatter technologies, cybersecurity training, and space components. This segment designs and manufactures modems, amplifiers, traveling wave tube amplifiers, frequency converters, and offers other associated software and services. The Allerium segment provides next-generation 911 (NG-911) infrastructure and solutions for state and local governments and carriers. Geographically, the company derives its key revenue from the USA.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.